Paul B Manning - Net Worth and Insider Trading

Paul B Manning Net Worth

The estimated net worth of Paul B Manning is at least $714 Million dollars as of 2024-04-26. Paul B Manning is the Director, 10% Owner of Dova Pharmaceuticals Inc and owns about 14,762,242 shares of Dova Pharmaceuticals Inc (DOVA) stock worth over $414 Million. Paul B Manning is the Director, 10% Owner of Verrica Pharmaceuticals Inc and owns about 15,589,481 shares of Verrica Pharmaceuticals Inc (VRCA) stock worth over $104 Million. Paul B Manning is also the Director of Liquidia Corp and owns about 5,965,784 shares of Liquidia Corp (LQDA) stock worth over $74 Million. Besides these, Paul B Manning also holds AveXis Inc (AVXS) , Taysha Gene Therapies Inc (TSHA) , Acumen Pharmaceuticals Inc (ABOS) , Candel Therapeutics Inc (CADL) . Details can be seen in Paul B Manning's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul B Manning has not made any transactions after 2023-12-14 and currently still holds the listed stock(s).

Transaction Summary of Paul B Manning

To

Paul B Manning Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul B Manning owns 8 companies in total, including Taysha Gene Therapies Inc (TSHA) , Verrica Pharmaceuticals Inc (VRCA) , and Dova Pharmaceuticals Inc (DOVA) among others .

Click here to see the complete history of Paul B Manning’s form 4 insider trades.

Insider Ownership Summary of Paul B Manning

Ticker Comapny Transaction Date Type of Owner
TSHA Taysha Gene Therapies Inc 2023-11-17 director & 10 percent owner
VRCA Verrica Pharmaceuticals Inc 2023-07-24 director & 10 percent owner
DOVA Dova Pharmaceuticals Inc 2019-11-12 director & 10 percent owner
AVXS AveXis Inc 2018-05-15 director & other: Former 10% Owner
ABOS Acumen Pharmaceuticals Inc 2021-07-06 10 percent owner
LQDA Liquidia Corp 2023-12-14 director & 10 percent owner
CADL Candel Therapeutics Inc 2021-07-29 director
KTTA Pasithea Therapeutics Corp 2022-10-22 10 percent owner

Paul B Manning Latest Holdings Summary

Paul B Manning currently owns a total of 7 stocks. Among these stocks, Paul B Manning owns 14,762,242 shares of Dova Pharmaceuticals Inc (DOVA) as of August 9, 2019, with a value of $414 Million and a weighting of 57.99%. Paul B Manning owns 15,589,481 shares of Verrica Pharmaceuticals Inc (VRCA) as of July 24, 2023, with a value of $104 Million and a weighting of 14.52%. Paul B Manning also owns 5,965,784 shares of Liquidia Corp (LQDA) as of December 14, 2023, with a value of $74 Million and a weighting of 10.34%. The other 4 stocks AveXis Inc (AVXS) , Taysha Gene Therapies Inc (TSHA) , Acumen Pharmaceuticals Inc (ABOS) , Candel Therapeutics Inc (CADL) have a combined weighting of 17.14% among all his current holdings.

Latest Holdings of Paul B Manning

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DOVA Dova Pharmaceuticals Inc 2019-08-09 14,762,242 28.04 413,933,266
VRCA Verrica Pharmaceuticals Inc 2023-07-24 15,589,481 6.65 103,670,049
LQDA Liquidia Corp 2023-12-14 5,965,784 12.37 73,796,748
AVXS AveXis Inc 2016-09-13 252,939 217.83 55,097,702
TSHA Taysha Gene Therapies Inc 2023-11-17 23,517,778 2.30 54,090,889
ABOS Acumen Pharmaceuticals Inc 2021-07-06 4,010,678 3.19 12,794,063
CADL Candel Therapeutics Inc 2021-07-29 56,000 6.43 360,080

Holding Weightings of Paul B Manning


Paul B Manning Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul B Manning has made a total of 1 transactions in Dova Pharmaceuticals Inc (DOVA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Dova Pharmaceuticals Inc is the acquisition of 28,062 shares on August 9, 2019, which cost Paul B Manning around $445,344.

According to the SEC Form 4 filings, Paul B Manning has made a total of 8 transactions in Verrica Pharmaceuticals Inc (VRCA) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Verrica Pharmaceuticals Inc is the acquisition of 200,000 shares on July 24, 2023, which cost Paul B Manning around $1 Million.

According to the SEC Form 4 filings, Paul B Manning has made a total of 3 transactions in Liquidia Corp (LQDA) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Liquidia Corp is the acquisition of 279,330 shares on December 14, 2023, which cost Paul B Manning around $2 Million.

More details on Paul B Manning's insider transactions can be found in the Insider Trading History of Paul B Manning table.

Insider Trading History of Paul B Manning

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul B Manning Trading Performance

GuruFocus tracks the stock performance after each of Paul B Manning's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul B Manning is 4.42%. GuruFocus also compares Paul B Manning's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul B Manning within 3 months outperforms 11 times out of 32 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Paul B Manning's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Paul B Manning

Average Return

-19.12%

Average return per transaction

Outperforming Transactions

38%

9 out of 24 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 8.71 4.42 -3.54 -19.12 -25.67 -9.23
Relative Return to S&P 500(%) 7.14 0.77 -7.86 -26.73 -33.16 -21.43

Paul B Manning Ownership Network

Ownership Network List of Paul B Manning

No Data

Ownership Network Relation of Paul B Manning


Paul B Manning Owned Company Details

What does Taysha Gene Therapies Inc do?

Who are the key executives at Taysha Gene Therapies Inc?

Paul B Manning is the director & 10 percent owner of Taysha Gene Therapies Inc. Other key executives at Taysha Gene Therapies Inc include Chief Financial Officer Kamran Alam , 10 percent owner Session R.a. Ii , and 10 percent owner Astellas Pharma Inc. .

Taysha Gene Therapies Inc (TSHA) Insider Trades Summary

Over the past 18 months, Paul B Manning made 3 insider transaction in Taysha Gene Therapies Inc (TSHA) with a net purchase of 18,066,667. Other recent insider transactions involving Taysha Gene Therapies Inc (TSHA) include a net sale of 549,095 shares made by Session R.a. Ii , a net purchase of 777,778 shares made by Stalfort John A Iii , and a net purchase of 444,444 shares made by Sean P. Nolan .

In summary, during the past 3 months, insiders sold 0 shares of Taysha Gene Therapies Inc (TSHA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 582,095 shares of Taysha Gene Therapies Inc (TSHA) were sold and 19,405,000 shares were bought by its insiders, resulting in a net purchase of 18,822,905 shares.

Taysha Gene Therapies Inc (TSHA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Taysha Gene Therapies Inc Insider Transactions

No Available Data

Paul B Manning Mailing Address

Above is the net worth, insider trading, and ownership report for Paul B Manning. You might contact Paul B Manning via mailing address: 200 Garrett Street Suite S, Charlottesville Va 22902.

Discussions on Paul B Manning

No discussions yet.